Erlotinib with or without bevacizumab as a first‐line therapy for patients with advanced nonsquamous epidermal growth factor receptor‐positive non‐small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study

Erlotinib with or without bevacizumab as a first‐line therapy for patients with advanced nonsquamous epidermal growth factor receptor‐positive non‐small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study

Abstract Background In the phase II JO25567 study (JapicCTI‐111390), erlotinib plus bevacizumab demonstrated a significant clinical benefit in Japanese patients with epidermal growth factor receptor mutation‐positive (EGFR+) non‐small cell lung cancer (NSCLC). Here, we present an exploratory analysi...

Full description

Bibliographic Details
Main Authors: Yukio Hosomi, Takashi Seto, Makoto Nishio, Koichi Goto, Noboru Yamamoto, Isamu Okamoto, Kosei Tajima, Yusuke Kajihara, Nobuyuki Yamamoto
Format: Article
Language:English
Published: Wiley 2022-08-01
Series:Thoracic Cancer
Subjects:
bevacizumab
EGFR
erlotinib
NSCLC
pleural/pericardial effusion
Online Access:https://doi.org/10.1111/1759-7714.14541

Internet

https://doi.org/10.1111/1759-7714.14541

Similar Items